N1 Life

About N1 Life

N1 Life operates as a biotechnology company, spun out from Stanford University in 2019, focused on creating new therapeutics for unmet medical needs in both humans and animals. The company was co-founded by Dr. Paul A. Wender, a Stanford professor and translational scientist, and Dr. Janice (Xiaoyu) Zang, an entrepreneurial scientist who was Dr. Wender's doctoral advisee. Their collaboration aims to translate over 30 years of research in drug delivery technology into practical clinical applications.

The core of N1 Life's business is its proprietary drug delivery technology designed to overcome the high failure rates in traditional drug development, which are often attributed to the complexity of human tissues. The company has developed two primary platforms: the Absotride™ peptide-based platform and the ChARLS™ polymer-based platform. These technologies act as molecular transporters, enabling therapeutic molecules of various sizes—from small molecules to mRNA/DNA—to penetrate biological barriers and reach diseased tissues more effectively. This approach enhances drug bioavailability and can reduce toxicity. The company's strategy often involves repurposing "old drugs for new uses," such as those with expired patents or that previously failed in late-stage trials, by combining them with their carrier technologies to create new peptide-drug conjugates (PDCs).

N1 Life's business model encompasses both developing its own in-house drug pipelines and engaging in co-development partnerships with other pharmaceutical and biotech companies. This dual approach allows the firm to leverage its platform's wide applicability across various therapeutic areas, including oncology, dermatology, ophthalmology, and infectious diseases. The company has secured $10 million in funding, including a Pre-A round led by Legend Capital, to advance its platform technologies and preclinical development. By improving delivery efficiency, N1 Life aims to significantly shorten the early drug development cycle and reduce overall costs, making novel treatments more accessible.